Full-Time

Associate Director

Clinical Quality Assurance and Compliance

Confirmed live in the last 24 hours

Invivyd

Invivyd

51-200 employees

Develops antibody therapies for viral protection

No salary listed

Senior

Waltham, MA, USA

Category
QA & Testing
Quality Assurance
Required Skills
Google Cloud Platform
Requirements
  • A bachelor’s degree in a scientific discipline or biotechnology field
  • A minimum of 6 years relevant GCP experience in pharma/biotech company, working within quality systems and regulated GCP/ICH environments
  • Experience leading and facilitating inspection readiness activities and hosting FDA and other regulatory agency inspections
  • Experience managing internal and external audits
  • Strong understanding of GCPs, FDA, and ICH regulatory standards/guidance documents
  • Extensive knowledge of risk-based quality systems approaches, with a focus on ICH E6 R2 GCP principles
  • Experience using Veeva Quality Vault
  • Ideally will also have experience in facilitating/participating in remote audits and quality activities; able to travel to Clinical sites/vendors as required; Travel Requirement expected to be up to 25%.
Responsibilities
  • Build the Clinical Quality Assurance and Compliance function and infrastructure to support Invivyd pipeline and other compliance-related activities
  • Participate on cross-functional team meetings as the Clinical Quality Assurance Subject Matter Expert (SME)
  • Create, implement, and maintain efficient, phase-appropriate, and compliant GCP, GLP, and GVP systems and policies/procedures
  • Partner with other stakeholders across the organization to develop and maintain cross-functional SOPs, policies, procedures, and systems/activities consistent with corporate objectives
  • Assist the Clinical Development organization in establishing procedures to support a risk-based approach to oversight of clinical trials using principles of quality by design and quality risk management
  • Proactively identify potential quality issues/discrepancies and work with Management to effectively resolve in a compliant and timely manner
  • Provide Clinical Quality Support for Clinical Vendor/CRO oversight
  • Represent Invivyd Clinical Quality on Sponsor/CRO/Site project calls and provide updates to Management
  • Provide Clinical Quality support for critical quality issues, protocol deviations, investigations, root causes, and CAPAs
  • Develop a risk-based audit program to conduct effective audits of internal processes, investigator sites, and vendors that support development activities
  • Establish clinical quality procedures and tools in support of audit and compliance activities
  • Collaborate with key stakeholders in development and implementation of internal and external GCP audit plans
  • Assist in the development, implementation, and maintenance of training and compliance programs
  • Directly responsible for GCP, GLP, and GVP training and conduct of associated training sessions as required
  • Partner with stakeholders on maintenance and implementation of other training across the organization (i.e., CMC Quality Assurance, IT, HR, Finance, Corporate Compliance, Medical Affairs) to ensure full compliance
  • Proactively provide key stakeholders with intelligence on changes and updates to ICH and GCP regulations and assess impact on Invivyd systems and practices
  • Lead strategy and activities in support of GCP, GLP, and GVP health authority inspections
  • Review regulatory clinical and nonclinical documents such as protocols, clinical study reports, IBs, ICFs, etc. and check for consistency and compliance with relevant regulations, standards, and best practices.
Desired Qualifications
  • Experience in facilitating/participating in remote audits and quality activities; able to travel to Clinical sites/vendors as required; Travel Requirement expected to be up to 25%.

Invivyd develops antibody-based therapies aimed at protecting individuals with weakened immune systems from viral threats. The company focuses on creating monoclonal antibodies that can provide protection where traditional vaccinations may fall short, particularly for immunocompromised patients. Their main product in development, VYD222, targets the prevention of symptomatic COVID-19 in vulnerable groups, such as organ transplant recipients and those with blood cancers. Invivyd differentiates itself by utilizing advanced technologies like viral surveillance and predictive modeling to optimize their antibody candidates. The company's goal is to safeguard at-risk populations from serious viral infections, starting with COVID-19 and potentially expanding to other viruses like influenza.

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased demand for therapies targeting immunocompromised populations aligns with Invivyd's focus.
  • AI-driven drug discovery platforms can enhance Invivyd's predictive modeling efforts.
  • Government funding expansion for pandemic preparedness could financially support Invivyd's projects.

What critics are saying

  • Investigation by Kahn Swick & Foti, LLC could lead to legal challenges.
  • Rapid virus evolution previously rendered an antibody candidate ineffective.
  • Reliance on external funding indicates potential financial vulnerability.

What makes Invivyd unique

  • Invivyd focuses on antibody-based therapies for immunocompromised individuals, a niche market.
  • The company uses advanced technologies like viral surveillance and predictive modeling.
  • Invivyd's lead candidate, VYD222, targets COVID-19 in vulnerable populations.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Professional Development Budget

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Quiver Quant
Apr 21st, 2025
Invivyd, Inc. Secures $30 Million Term Loan Facility from Silicon Valley Bank to Advance Viral Infectious Disease Pipeline

Invivyd secures a $30 million loan from Silicon Valley Bank to advance its COVID-19 treatment candidate VYD2311.Quiver AI SummaryInvivyd, Inc. announced a $30 million term loan agreement with Silicon Valley Bank to support its biopharmaceutical initiatives, particularly in relation to its candidate monoclonal antibody, VYD2311, which targets COVID-19 and aims to enhance prophylactic and therapeutic options. The loan allows for future capital draw

Africa Business Watch
Aug 10th, 2023
INVIVYD INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Invivyd, Inc. - IVVD, ADGI

Adagio, formed in June 2020 to develop drugs for the treatment and prevention of COVID-19, conducted its initial public offering ("IPO") in August 2021.

News18
Jul 29th, 2023
'Making A difference': Zerodha's Nikhil kamath, Biocon's Kiran Mazumdar Shaw pledge Rs 50 lakh to charity

Biocon is collaborating with US firm Adagio Therapeutics to develop ADG20, an antibody therapy for preventing and treating the Coronavirus and its variants.

Business Wire
Jul 7th, 2023
INVIVYD INVESTIGATION INITIATED by former Louisiana Attorney general: Kahn Swick & Foti, LLC investigates the officers and directors of Invivyd, Inc. – IVVD, ADGI

Adagio, formed in June 2020 to develop drugs for the treatment and prevention of COVID-19, conducted its initial public offering (“IPO”) in August 2021.

Nature
Jun 28th, 2023
No drug for COVID: ‘the most successful failure in my life’

Adagio raised more than US$450 million in funding during its first two years and carried out several clinical trials before disappointment struck when the SARS-CoV-2 virus evolved and the firm’s antibody candidate was no longer effective.